Jubilant Therapeutics Inc

6 articles about Jubilant Therapeutics Inc

• 

  Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer...

  6/23/2023

  Jubilant Therapeutics' differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.

• Jubilant Therapeutics Inc. Appoints Nadir Patel as an Independent Member of Its Board of Directors

  6/15/2023

  Jubilant Therapeutics Inc. announced the appointment of Nadir Patel as an independent director on the Company's Board of Directors.

• Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models

  4/13/2023

  Jubilant Therapeutics Inc today announced publication of novel research demonstrating that a highly selective, non-competitive and orally administered inhibitor of Protein Arginine Deiminase 4 (PAD4), showed remarkable efficacy in two animal models of Rheumatoid Arthritis (RA).

• Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM)

  2/13/2023

  Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for JBI-778 for the treatment of Glioblastoma Multiforme (GBM).

• Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021

  4/10/2021

  JBI-778, a brain penetrant PRMT5 inhibitor demonstrated significant tumor growth inhibition in glioblastoma in addition to its activity against a number of other cancers

• Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers

  12/7/2020

  Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced efficacy data from a study of JBI-802, its novel dual inhibitor of LSD1-HDAC6, in multiple acute myeloid leukemia (AML) models, and the identificat